database / hormone
Octreotide
also known as Sandostatin
Skeletal structure drawn from the computed atomic coordinates in PubChem CID 448601. Carbons are implicit vertices; hydrogens on carbon are suppressed, as in any structural formula. Nothing here is estimated — every atom sits where PubChem placed it.
Research reference only. The observations below are recorded in the cited literature. Nothing here is advice or a recommendation, and no dosing information is published on this site.
Sequence
Primary structure not characterised in the public records this index draws on. Nothing is shown rather than something invented.
D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr(ol) — a disulfide-cyclised octapeptide with D-residues and a C-terminal amino alcohol.
Molecular data
| molecular formula | C49H66N10O10S2 |
|---|---|
| molecular weight | 1019.2 Da (PubChem) |
| computed backbone mass | not characterised |
| length | not characterised |
| net charge (pH 7.4) | not characterised |
| mean hydropathy | not characterised |
| half-life | not characterised |
| delivery route | subcutaneous, intramuscular |
| PubChem CID | 448601 |
| PDB | not characterised |
| UniProt parent | not characterised |
Mechanism
Somatostatin analogue with SSTR2/SSTR5 selectivity.
Reported targets: SSTR2 SSTR5
Experimental structure
No experimental structure of this peptide is deposited in the PDB. Nothing is rendered here — a predicted fold would not be a structure, and this site does not draw one.
Reported effects
Each row is an outcome described in the literature indexed for this peptide. Reported in the cited work — not a claim, not a recommendation.
| reported outcome | where it appears |
|---|---|
| GH suppression | Acromegaly Secondary to Ectopic Growth Hormone-Releasing Hormone Secretion F… Cureus 2026 |
| acromegaly outcomes in trials | Octreotide and direct/indirect lung injury Research in pharmaceutical sciences 2025 |
Registered trials
| NCT | title | status | phase |
|---|---|---|---|
| NCT00113360 | RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinom | COMPLETED | PHASE2 |
| NCT01137682 | Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreo | COMPLETED | PHASE3 |
| NCT05361668 | Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoi | COMPLETED | PHASE2 |
| NCT00383708 | Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients | COMPLETED | PHASE3 |
| NCT00049023 | Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors | COMPLETED | PHASE1 |
Literature (8)
Acromegaly Secondary to Ectopic Growth Hormone-Releasing Hormone Secretion From Metastatic Bronchial Carcinoid Tumor: A Case Report — Cureus 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 42571548 · DOI 10.7759/cureus.112355
Octreotide and direct/indirect lung injury — Research in pharmaceutical sciences 2025
Background and purposeLung injury is one of the most important diseases, which is accompanied by hypoxemia, organ failure, and a high mortality rate. There are several symptoms and causes of lung injuries. In the past years, special attention has been given to investigating the pathophysiology and the treatment of this disease. Octreotide, as an anti-inflammatory, anti-secretory, tissue-repairing, and anti-fibrotic drug, has been considered and administered for the treatment of lung injury. This review article considered the pharmacological effects of octreotide on physiopathological conditions in patients or animal models that have direct or indirect lung injury.Search strategy and findingsKeywords including "octreotide" OR "sandostatin" AND "lung injury" OR "ARDS" OR "respiratory distress" OR "lung fibrosis" were searched in the database of PubMed, and 44 articles were found. According…
open access ↗ · PMID 40933598 · DOI 10.4103/rps.rps_67_24
A Case Report: Fatal Mesenteric Microvascular Compromise Following Methamphetamine use and Insulin Overdose Treated with Octreotide — South Dakota medicine : the journal of the South Dakota State Medical Association 2025
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 42470334
Long-Term Results of Long-Acting Somatostatin Analog Therapy in Children with Congenital Hyperinsulinism — Journal of clinical research in pediatric endocrinology 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 42619456 · DOI 10.4274/jcrpe.galenos.2026.2026-3-12
Impact of Duration of Intravenous Octreotide Infusion on Achieving Hemostasis in Patients With Acute Variceal Hemorrhage — The Annals of pharmacotherapy 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 42661447 · DOI 10.1177/10600280261478164
Octreotide as Adjunctive Therapy for Catecholamine-Secreting Pheochromocytoma and Paraganglioma — The Journal of clinical endocrinology and metabolism 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 42626938 · DOI 10.1210/clinem/dgag343
Octreotide-assisted endoscopy versus octreotide-assisted TIPS for acute esophagogastric variceal bleeding with and without terlipressin intensification: A real-world study — Research Square 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · DOI 10.21203/rs.3.rs-10679798/v1
Combined SSTR2-targeted Analogue with <sup>177</sup>Lu-DOTATATE radionuclide and octreotide therapy for refractory meningioma: a case report — Frontiers in oncology 2026
Meningiomas are the most common primary intracranial tumor in adults. Beyond surgery and radiation, no standard of care therapy exists. Meningiomas overexpress somatostatin receptor 2 (SSTR2), providing the rationale for somatostatin analogue-based therapies, including octreotide. The addition of everolimus, a mammalian target of rapamycin inhibitor, to octreotide marginally improves the 6-month progression-free survival (PFS) rate. For this reason, novel therapies have emerged for the treatment of refractory meningiomas, including somatostatin receptor targeted radionuclide therapy. However, preliminary results with refractory meningiomas treated with single agent 177Lu-DOTATATE, a β-emitting peptide receptor radionuclide therapy (PRRT), demonstrated outcomes comparable to those observed with combination octreotide and everolimus. In contrast, in neuroendocrine tumors (NETs), octreotide…
open access ↗ · PMID 42370133 · DOI 10.3389/fonc.2026.1820428
Related
Glucagon
hormone · 8 citations
Ghrelin
hormone · 8 citations
Oxytocin
hormone · 8 citations
Vasopressin
hormone · 8 citations
Gonadorelin
hormone · 8 citations
Kisspeptin-10
hormone · 8 citations